Form 4: Pulse Biosciences Director Exercises Warrants, Acquires Shares

Robert W. Duggan, a director at Pulse Biosciences, exercised warrants to purchase shares of the company's common stock at $11 per share on December 18, 2024.

Summary

• On December 18, 2024, Robert W. Duggan, a director of Pulse Biosciences, exercised warrants to acquire shares of the company's common stock.
• The exercise price was $11.00 per share.
• Mr. Duggan acquired 5,187,824 shares directly and an additional 69,020 shares indirectly through an affiliated company, Genius 24C Inc.
• He also acquired 49,312 shares indirectly through another affiliated company, Blazon Corporation.
• The warrants were acquired through a previous rights offering where each unit consisted of one share of common stock and two warrants to purchase one half share of common stock at $11.00 per whole share.
• The warrants expire on July 3, 2029.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive as it reflects a director exercising warrants, which can be seen as a sign of confidence, but it is a routine transaction.

Positives

• The exercise of warrants by a director demonstrates confidence in the company's future prospects.
• The acquisition of a significant number of shares by a director can be seen as a positive signal to the market.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who make transactions in their company's stock. It is a routine disclosure required by law.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, and this filing is consistent with those requirements.
• The transaction is similar to other insider transactions where executives exercise options or warrants to acquire shares.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates

Keywords

warrants, stock, shares, director, exercise, rights offering, Pulse Biosciences, PLSE, insider trading